Developer docs
API playgroundTry for free, no card

Search company profiles

Palette Life Sciences

Full company profile

uuid000293i

Namestring
Palette Life Sciences
Legal namestring
Palette Life Sciences
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

Palette Life Sciences is a Swedish medical device company that developed minimally invasive injectable treatments — Barrigel (rectal spacer for radiation therapy), Deflux (pediatric vesicoureteral reflux), and Solesta (fecal incontinence) — serving healthcare providers in gastroenterology, urology, and radiation oncology. Acquired by Teleflex in October 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimally invasive treatments, medical device products, rectal spacer implants, urology treatments, gastroenterology therapies
Industry2 codes
PRIMARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYHSABAKAH
Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies)
Home & Personal Services/Elder Care & In-Home Care Services/Medical Equipment & Home Mobility Support Services
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Medical Devices (Minimally Invasive Gastroenterology and Urology)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical device and treatment product sales
TypeHardware Sales
Description

Revenue generated through the sale of minimally invasive medical treatment products including Barrigel, Deflux, and Solesta for gastroenterology and urology applications. Following acquisition by Teleflex in October 2023, operations are integrated into Teleflex's medical device business.

abfjournal.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Barrigel
Description

A flagship minimally invasive treatment product.

palettelifesciences.com
+2 more records
Core offering1 text field

Palette Life Sciences develops and markets minimally invasive medical device products for gastrointestinal and urological conditions. Its portfolio includes Barrigel, a hyaluronic acid-based rectal spacer used during radiation therapy; Deflux, an injectable treatment for pediatric vesicoureteral reflux; and Solesta, an injectable therapy for fecal incontinence. Following its October 2023 acquisition by Teleflex, the products continue to be sold under their respective brand names through Teleflex's medical device infrastructure.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Barrigel
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Danish medical device company with a leading continence care and ostomy portfolio directly comparable to Palette's Solesta fecal incontinence franchise and adjacent to its urology offerings. Competes in the same specialist customer base and minimally invasive treatment category.

2Cook Medical
TypeDirect peer
Description

U.S. privately-held medical device manufacturer with deep gastroenterology and urology portfolios, directly comparable to Palette's GI/urology focus. Competes for the same specialist physician customers across minimally invasive procedural categories.

TypeBroad incumbent
Description

Global leader in gastroenterology endoscopy and related minimally invasive devices. A broad incumbent whose GI franchise overlaps with Barrigel-adjacent clinical workflows and competes for the same gastroenterology specialist customers.

TypeBroad incumbent
Description

Large diversified medical device company with material gastroenterology and urology franchises. Operates broadly across minimally invasive procedural categories overlapping with Palette's specialty focus.

TypeBroad incumbent
Description

Medical device company with gastroenterology and general surgery product lines overlapping with Palette's minimally invasive procedural focus. Broad incumbent competing for similar hospital budgets.

TypeDirect peer
Description

Medical device company with meaningful gastroenterology and urology product lines, including devices used in interventional procedures directly comparable to Palette's minimally invasive treatment approach.

TypeDirect peer
Description

Specialty medical technology company focused on urology and pelvic health, directly comparable to Palette's Deflux pediatric urology franchise. Competes for the same specialist urology customer base.

TypeDirect peer
Description

Private medical products company with continence care and ostomy portfolios directly comparable to Palette's Solesta franchise. Competes for the same incontinence specialist and patient channels.

TypeDirect peer
Description

Mölnlycke-owned urology and continence care company directly competing in the same specialist categories as Palette's Deflux and Solesta franchises.

TypeOthers
Description

Parent company following the October 2023 acquisition. Functions as both owner and adjacent competitor, with its own urology and interventional medical device franchises that may overlap with Palette's portfolio at the corporate level.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Palette Life Sciences

Medical Devices (Minimally Invasive Gastroenterology and Urology)palettelifesciences.com

Palette Life Sciences is a Swedish medical device company that developed minimally invasive injectable treatments — Barrigel (rectal spacer for radiation therapy), Deflux (pediatric vesicoureteral reflux), and Solesta (fecal incontinence) — serving healthcare providers in gastroenterology, urology, and radiation oncology. Acquired by Teleflex in October 2023.

Palette Life Sciences firmographics

Firmographics
Name
Palette Life Sciences
Legal name
Palette Life Sciences
Website
https://palettelifesciences.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Palette Life Sciences is a Swedish medical device company that developed minimally invasive injectable treatments — Barrigel (rectal spacer for radiation therapy), Deflux (pediatric vesicoureteral reflux), and Solesta (fecal incontinence) — serving healthcare providers in gastroenterology, urology, and radiation oncology. Acquired by Teleflex in October 2023.
Ownership category
akta.pro rank

Palette Life Sciences industry classification

Industry
Product category
Medical Devices (Minimally Invasive Gastroenterology and Urology)
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHANAG
Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYHSABAKAH
Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies)
Home & Personal Services/Elder Care & In-Home Care Services/Medical Equipment & Home Mobility Support Services

Keywords

  • Minimally invasive treatments
  • Medical device products
  • Rectal spacer implants
  • Urology treatments
  • Gastroenterology therapies

Where Palette Life Sciences is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Palette Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

  1. Medical device and treatment product sales: Revenue generated through the sale of minimally invasive medical treatment products including Barrigel, Deflux, and Solesta for gastroenterology and urology applications. Following acquisition by Teleflex in October 2023, operations are integrated into Teleflex's medical device business.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Palette Life Sciences product offering

Product offering

Core offering

Palette Life Sciences develops and markets minimally invasive medical device products for gastrointestinal and urological conditions. Its portfolio includes Barrigel, a hyaluronic acid-based rectal spacer used during radiation therapy; Deflux, an injectable treatment for pediatric vesicoureteral reflux; and Solesta, an injectable therapy for fecal incontinence. Following its October 2023 acquisition by Teleflex, the products continue to be sold under their respective brand names through Teleflex's medical device infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

  • Barrigel: A flagship minimally invasive treatment product.
  • Deflux
  • Solesta

Products and services

  • Barrigel

Companies that use Palette Life Sciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Palette Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Palette Life Sciences partnerships and signals

Strategic signal

Scale indicators3 records

Palette Life Sciences competitors and assessment

Company assessment

Direct peers

  • Coloplast: Danish medical device company with a leading continence care and ostomy portfolio directly comparable to Palette's Solesta fecal incontinence franchise and adjacent to its urology offerings. Competes in the same specialist customer base and minimally invasive treatment category.
  • Cook Medical: U.S. privately-held medical device manufacturer with deep gastroenterology and urology portfolios, directly comparable to Palette's GI/urology focus. Competes for the same specialist physician customers across minimally invasive procedural categories.
  • Merit Medical Systems: Medical device company with meaningful gastroenterology and urology product lines, including devices used in interventional procedures directly comparable to Palette's minimally invasive treatment approach.
  • Laborie Medical Technologies: Specialty medical technology company focused on urology and pelvic health, directly comparable to Palette's Deflux pediatric urology franchise. Competes for the same specialist urology customer base.
  • Hollister Incorporated: Private medical products company with continence care and ostomy portfolios directly comparable to Palette's Solesta franchise. Competes for the same incontinence specialist and patient channels.
  • Wellspect Healthcare: Mölnlycke-owned urology and continence care company directly competing in the same specialist categories as Palette's Deflux and Solesta franchises.

Broad incumbents

  • Olympus Corporation: Global leader in gastroenterology endoscopy and related minimally invasive devices. A broad incumbent whose GI franchise overlaps with Barrigel-adjacent clinical workflows and competes for the same gastroenterology specialist customers.
  • Boston Scientific: Large diversified medical device company with material gastroenterology and urology franchises. Operates broadly across minimally invasive procedural categories overlapping with Palette's specialty focus.
  • Conmed Corporation: Medical device company with gastroenterology and general surgery product lines overlapping with Palette's minimally invasive procedural focus. Broad incumbent competing for similar hospital budgets.

Others

  • Teleflex Incorporated: Parent company following the October 2023 acquisition. Functions as both owner and adjacent competitor, with its own urology and interventional medical device franchises that may overlap with Palette's portfolio at the corporate level.

Market position

Customer concentration

Palette Life Sciences social profiles

Digital presence

Palette Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Palette Life Sciences leadership team

Management profile

Number of profiles

Profiles6 records

Palette Life Sciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Palette Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Palette Life Sciences

What does Palette Life Sciences do?

Palette Life Sciences develops and markets minimally invasive medical device products for gastrointestinal and urological conditions. Its portfolio includes Barrigel, a hyaluronic acid-based rectal spacer used during radiation therapy; Deflux, an injectable treatment for pediatric vesicoureteral reflux; and Solesta, an injectable therapy for fecal incontinence. Following its October 2023 acquisition by Teleflex, the products continue to be sold under their respective brand names through Teleflex's medical device infrastructure.

Is Palette Life Sciences a public or private company?

Palette Life Sciences is a private company. It is classified as corporate owned and is currently acquired.

When was Palette Life Sciences founded?

Palette Life Sciences was founded in 2018. It employs 11 to 50 people.

Where is Palette Life Sciences based?

Palette Life Sciences is headquartered in Stockholm, Sweden, in the Europe region.

How does Palette Life Sciences make money?

One revenue line is on record: medical device and treatment product sales.

Who are Palette Life Sciences's main competitors?

Direct peers on record are Coloplast, Cook Medical, Merit Medical Systems, Laborie Medical Technologies, Hollister Incorporated and Wellspect Healthcare. Broad incumbents are Olympus Corporation, Boston Scientific and Conmed Corporation. Teleflex Incorporated is listed as an others.

Does Palette Life Sciences have an API?

No public API is recorded for Palette Life Sciences.

What industry is Palette Life Sciences in?

Palette Life Sciences's product category is Medical Devices (Minimally Invasive Gastroenterology and Urology). Its primary akta.pro industry code is HLAHANAG, Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs), with a secondary code of HSABAKAH, Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTeleflex Completes Acquisition of Palette Life SciencesTeleflex completed its acquisition of Palette Life Sciences, adding Barrigel, Deflux, and Solesta to its portfolio. The deal paid $600 million upfront, with up to $50 million more on milestones, and is expected to be $0.25 dilutive to adjusted EPS in 2023.GlobeNewswirePalette Life Sciences Enters Into Definitive Agreement with Teleflex IncorporatedPalette Life Sciences entered a definitive agreement to be acquired by Teleflex for $600 million upfront, plus up to $50 million on commercial milestones. The deal is expected to close in Q4 2023 and will expand the NASHA-based product portfolio, including Barrigel, Deflux, and Solesta.GlobeNewswireTeleflex to Acquire Palette Life SciencesTeleflex agreed to acquire privately-held Palette Life Sciences for $600 million upfront, plus up to $50 million on milestones, with closing expected in Q4 2023. The deal expands Teleflex's Interventional Urology portfolio with NASHA products, including Barrigel, and is expected to be accretive to adjusted gross margin.BenzingaTeleflex Acquires Palette Life Sciences For $600M Upfront, Expands Interventional Urology Portfolio - TelTeleflex Incorporated has agreed to acquire privately-held Palette Life Sciences AB for an upfront cash payment of $600 million, with up to an additional $50 million tied to commercial milestones. The acquisition will expand Teleflex's Interventional Urology portfolio to include NASHA spacer and tissue bulking products, with Palette Life Sciences estimated to generate approximately $56 million in 2023 net sales. The transaction is expected to be dilutive to adjusted EPS in 2023-2024 but accretive beginning in fiscal year 2025, with the company projecting high-teens to low 20% year-over-year revenue growth for the acquired business in 2024.GlobeNewswireTeleflex to Acquire Palette Life SciencesTeleflex agreed to acquire privately-held Palette Life Sciences for $600 million upfront, plus up to $50 million on milestones, with closing expected in Q4 2023. The deal expands Teleflex's Interventional Urology portfolio with NASHA spacer products, including Barrigel, and is expected to be accretive to adjusted gross margin.GlobeNewswirePalette Life Sciences Welcomes New Barrigel® Center of Excellence Program DesignationsPalette Life Sciences announced new Barrigel Center of Excellence designations for May, recognizing physicians and institutions for exceptional clinical expertise in the Barrigel procedure. The designations include John Han-Chih Chang, Glen Gejerman, Suraj Singh, and Dan Welchons, among others. Barrigel is a hyaluronic acid rectal spacer that reduces side effects from prostate cancer radiation therapy.GlobeNewswirePalette Life Sciences Announces Launch of Barrigel® Center of Excellence Program and First DesignationsPalette Life Sciences launched the Barrigel Center of Excellence program, recognizing physicians with exceptional clinical expertise in the Barrigel procedure. The first designations include five physicians and institutions across the U.S. for their commitment to minimizing side effects of prostate radiation therapy.GlobeNewswirePalette Life Sciences Announces Transaction With Global Healthcare Investor OrbiMedPalette Life Sciences entered a debt financing facility with OrbiMed for up to $75 million, with $50 million available at closing. The non-dilutive capital will support global expansion of its product portfolio, including Barrigel in the United States. Proceeds will also pay off an outstanding balance under its Silicon Valley Bank credit facility.GlobeNewswirePalette Life Sciences Announces Transaction With Global Investment Leader OrbiMedPalette Life Sciences entered a debt financing facility with OrbiMed for up to $75 million, with $50 million available at closing. The non-dilutive capital will support global expansion of its product portfolio, including Barrigel in the United States. Proceeds will also pay off an outstanding balance under its Silicon Valley Bank credit facility.GlobeNewswirePalette Life Sciences Announces Transaction With Global Healthcare Investor OrbiMedPalette Life Sciences entered a debt financing facility with OrbiMed for up to $75 million, with $50 million available at closing. The capital will support global expansion, including Barrigel in the US, and pay off a Silicon Valley Bank credit facility.